Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML2146

Sigma-Aldrich

SR-18292 Maleate

≥98% (HPLC)

Synonym(s):

SR-18292 Maleate, 1-[(1,1-Dimethylethyl)[(4-methylphenyl)methyl]amino]-3-(1H-indol-4-yloxy)-2-propanol maleate, SR 18292, SR 18292 maleate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H30N2O2 · C4H4O4
CAS Number:
2095432-55-4
Molecular Weight:
482.57
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC(C)(C)N(CC(O)COC1=CC=CC2=C1C=CN2)CC3=CC=C(C)C=C3.O=C(O)/C=C\C(O)=O

Application

SR-18292 Maleate has been used as a peroxisome proliferator-activated receptor γ coactivator 1 α (PGC1α) inhibitor to study the protective effects of pioglitazone on demyelinated axons.

Biochem/physiol Actions

SR-18292 is a potent and specific inhibitor of hepatic gluconeogenesis via increased acetylation of PGC-1α and suppression of gluconeogenic gene expression. SR-18292 reduces blood glucose and increases hepatic insulin sensitivity in mouse models of T2D.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kfir Sharabi et al.
Cell, 169(1), 148-160 (2017-03-25)
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1α acetylation in the liver
Simon Licht-Mayer et al.
Acta neuropathologica, 140(2), 143-167 (2020-06-24)
Axonal loss is the key pathological substrate of neurological disability in demyelinating disorders, including multiple sclerosis (MS). However, the consequences of demyelination on neuronal and axonal biology are poorly understood. The abundance of mitochondria in demyelinated axons in MS raises

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service